Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Emergent BioSolutions Inc. Director's Dealing 2019

Jun 4, 2019

32870_dirs_2019-06-03_5c99affa-de2f-4b66-8707-0f725fa89235.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2019-05-23

Reporting Person: Emergent BioSolutions Inc. (Sean Kirk, EVP, Manufacturing)

Holdings (Non-Derivative)

Security Shares Ownership
Common Stock 13604 Direct

Holdings (Derivative)

Security Exercise Price Expiration Underlying Shares Ownership
Stock Options (Right to Buy) $30.86 2023-02-28 Common Stock (3135.0) Direct
Stock Options (Right to Buy) $30.63 2024-02-27 Common Stock (7293.0) Direct
Stock Options (Right to Buy) $49.64 2025-02-26 Common Stock (6044.0) Direct
Stock Options (Right to Buy) $61.01 2026-02-25 Common Stock (5124.0) Direct
Stock Options (Right to Buy) $50.52 2026-03-31 Common Stock (1424.0) Direct

Footnotes

F1: Consists of 2,933 shares, as well as 1,424 unvested PSUs and 9,247 unvested RSUs granted from the Emergent Stock Incentive Plan. Each RSU and each PSU represents a right to receive one share of common stock. The PSUs vest upon achievement with respect to adjusted net income as a percentage of total GAAP revenue for the 2021 fiscal year, as certified by the Compensation Committee following the performance period. The RSUs vest in three equal installments annually on the day prior to the anniversary date of the grant.

F2: Vests in three equal annual installments beginning on the day prior to the anniversary date of the grant.